|
|
|
|
|
|
|
22.09.25 - 08:03
|
TME Pharma Announces Date of Publication of Half Year Results and CEO Share Purchase (Business Wire)
|
|
|
BERLIN--(BUSINESS WIRE)--Regulatory News:
TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for cancer and eye diseases, announces today that its half year results will be published on 30 October 2025. The closed period for insiders of the Company will start next week, 30 days before the publication of the half-year results on October 30, 2025.
TME Pharma additionally announces that it has received notification that Diede Van Den Ouden, Chief Executive Officer and a Person Discharging Managerial Responsibilities ("PDMR"), has purchased an additional 300,000 ordinary shares in the Company at an average price per share of €0.0927. The shares were acquired through an on-market transaction on Euronext Growth Paris on Friday 19 September 2025. Following this transaction, Mr Van Ouden holds a total of 2,300,000 ordinary shares.
Statement from the CEO
“My share purchases are an indication of my strong belief in ...
|
|
|
25.06.25 - 18:06
|
TME Pharma Appoints Diede van den Ouden as New CEO at the 2025 Annual General Meeting of Shareholders (Business Wire)
|
|
|
BERLIN--(BUSINESS WIRE)--Regulatory News:
TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today the unanimous approval of all resolutions submitted to its 2025 annual general meeting of shareholders (AGM), including the appointment of Diede van den Ouden as sole member of the board of directors and Chief Executive Officer as a successor to Aram Mangasarian. The shareholders representing 16.67% of the total issued and outstanding share capital on May 28, 2025, were represented at the AGM which took place on June 25, 2025, at 03:00 p.m. CEST.
“On behalf of the Board and the entire TME Pharma team I would like to welcome Diede van den Ouden as our new CEO. Diede's commitment to TME Pharma, demonstrated both as a significant shareholder and an active supporter, gives us great confidence as we enter this next chapter,” said Maurizio PetitBon, Chairma...
|
|
|
05.05.25 - 08:06
|
TME Pharma Announces New Strategy (Business Wire)
|
|
|
Diede van den Ouden, an experienced CEO with successful background in small-cap turnarounds, to be nominated for appointment as CEO at upcoming AGM in June 2025
Operational costs to be strongly reduced through outsourced staffing model as from July 1, 2025 while maintaining the ability to advance both NOX-A12 and NOX-E36 assets
Streamlined Supervisory Board with two members stepping down at upcoming AGM
Management confident in securing non-dilutive financing to cover short-term operational needs
Support for the new strategy and CEO nomination from existing shareholders with significant shareholdings
BERLIN--(BUSINESS WIRE)--Regulatory News:
TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announces today a strategic change to facilitate ongoing efforts to finance the next clinical trial for NOX-A12 through agreements with pharma or financial partners.
The strat...
|
|
|
25.04.25 - 18:06
|
TME Pharma Publishes 2024 Financial Results and Provides Operating Update (Business Wire)
|
|
|
Total €7.6 million raised through multiple transactions
All convertible debt instruments removed from balance sheet during 2024
Commitment to lean cost structure while focusing on completing strategic goals
Next clinical development steps for NOX-A12 validated by regulators
Pursuit of several transaction structures in parallel for the company's drug candidates
BERLIN--(BUSINESS WIRE)--Regulatory News:
TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announces today its financial results for the fiscal year ending December 31, 2024, and provides a business update.
The Annual Report 2024, as approved by the management and supervisory boards on April 24, 2025, is available on TME Pharma's website (www.tmepharma.com).
“TME Pharma achieved a number of significant clinical and regulatory milestones in 2024 and, as 2025 progresses, we remain committed to advanci...
|
|
|
20.01.25 - 18:03
|
TME Pharma: Half-yearly Report on the Liquidity Contract With Invest Securities (Business Wire)
|
|
|
BERLIN--(BUSINESS WIRE)--Regulatory News:
TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today that pursuant to the liquidity contract entrusted to Invest Securities by TME Pharma N.V. the assets outlined below appeared on the liquidity account as of December 31, 2024.
The following assets appeared on the liquidity account as of December 31, 2024:
Number of shares: 73,874
Cash balance of the liquidity account: €9,914.70
For the period July 1, 2024 – December 31, 2024:
Total number of shares bought: 252,021
representing an amount of: €32,739.89
representing total transactions of: 367
Total number of shares sold: 241,899
representing an amount of: €33,577.49
representing total transactions of: 338
As a reminder, the following assets appeared on the liquidity account as of June 30, 2024:
Number of shares: 63,403
Cash balance of the liquidity ac...
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
